Results 211 to 220 of about 64,054 (239)
Some of the next articles are maybe not open access.
Head & Neck, 2020
AbstractBackgroundRecurrent immunotherapy‐induced audiovestibular toxicity despite cessation of therapy has not been reported.MethodsWe report the first case of recurrent audiovestibular toxicity following immune‐checkpoint inhibitor (ICI) therapy. The patient was seen with sudden bilateral hearing loss and disequilibrium.
Jonathan S. Choi +5 more
openaire +2 more sources
AbstractBackgroundRecurrent immunotherapy‐induced audiovestibular toxicity despite cessation of therapy has not been reported.MethodsWe report the first case of recurrent audiovestibular toxicity following immune‐checkpoint inhibitor (ICI) therapy. The patient was seen with sudden bilateral hearing loss and disequilibrium.
Jonathan S. Choi +5 more
openaire +2 more sources
Journal of Neurology
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but can induce neurological immune-related adverse events (n-irAEs).We aimed at evaluating the occurrence and characteristics of n-irAEs in cancer patients treated with ICIs and identifying biomarkers predictive of such complications in a single-center case-control study in the ...
Marsili L. +11 more
openaire +3 more sources
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but can induce neurological immune-related adverse events (n-irAEs).We aimed at evaluating the occurrence and characteristics of n-irAEs in cancer patients treated with ICIs and identifying biomarkers predictive of such complications in a single-center case-control study in the ...
Marsili L. +11 more
openaire +3 more sources
Neurologic Immune-related Adverse Events of Immune Checkpoint Inhibitors (P1-1.Virtual)
Neurology, 2022Chen Yan +6 more
openaire +1 more source
Arquivos de Neuro-Psiquiatria
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system’s ability to recognize and attack tumor cells. Despite their clinical benefits, ICIs are associated with a range of immune-related adverse events (irAEs), including neurological toxicities.
Diogo Haddad Santos +5 more
openaire +1 more source
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system’s ability to recognize and attack tumor cells. Despite their clinical benefits, ICIs are associated with a range of immune-related adverse events (irAEs), including neurological toxicities.
Diogo Haddad Santos +5 more
openaire +1 more source
Neurologic Immune-Related Adverse Events in Oncology Care
JAMA Neurology, 2016openaire +2 more sources
Neurological immune-related adverse events with immune checkpoint inhibitors: collaboration is key
Journal of Neurology, Neurosurgery & PsychiatryAnadil Javaid +2 more
openaire +2 more sources
A Review of Cancer Immunotherapy Toxicity
Ca-A Cancer Journal for Clinicians, 2020Lucy Boyce Kennedy
exaly

